BLFS
NASDAQ
US
BioLife Solutions, Inc. - Common Stock
$19.51
▲ +$0.22
(+1.14%)
Vol 209K
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.2B
ROE
-0.9%
Margin
-20.2%
D/E
2.12
Beta
1.93
52W
$19–$30
Wall Street Consensus
16 analysts · Apr 20264
Strong Buy
11
Buy
1
Hold
0
Sell
0
Strong Sell
93.8%
Buy Rating
Price Chart
Similar Stocks
SHC
Sotera Health Co
P/E 90.4
$5.0B
TXG
10X Genomics Inc
$2.1B
ADPT
Adaptive Biotechnologies Corp
$2.5B
AZTA
Azenta Inc
$1.5B
FTRE
Fortrea Holdings Inc
$1.6B
PSNL
Personalis Inc
$706.9M
CTKB
Cytek Biosciences Inc
$645.7M
MLAB
Mesa Laboratories Inc
$433.5M
CYRX
Cryoport Inc
P/E 7.1
$480.7M
MRVI
Maravai LifeSciences Holdings Inc
$831.0M
Earnings
Beat rate: 100.0%
Next Report
May 06, 2026
EPS Estimate: $0.02
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $0.02 | — | — |
| Dec 2025 | $-0.02 | $0.22 | +$0.24 |
| Sep 2025 | $-0.01 | $0.01 | +$0.02 |
| Jun 2025 | $-0.04 | $-0.01 | +$0.03 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | -$3.4M | $23.9M | $25.4M | $28.1M | $18.8M |
| Net Income | — | $12.5M | -$448K | -$15.8M | $621K | $11.1M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -1.6% | -1.6% | -1.6% | -1.6% | -0.9% | -0.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -62.3% | -22.5% | -22.5% | -22.5% | -20.2% | -20.2% |
| Gross Margin | 64.6% | 60.7% | 60.7% | 60.7% | 64.8% | 64.8% |
| D/E Ratio | 2.90 | 2.90 | 2.90 | 2.90 | 2.12 | 2.12 |
| Current Ratio | 4.43 | 4.43 | 4.43 | 4.43 | 4.66 | 4.66 |
Key Ratios
ROA (TTM)
-0.8%
P/S (TTM)
15.73
P/B
3.4
EPS (TTM)
$-0.06
CF/Share
$-2.09
Rev Growth 3Y
-11.6%
52W High
$29.62
52W Low
$19.10
$19.10
52-Week Range
$29.62
Financial Health
Free Cash Flow
-$9.6M
Net Debt
-$15.1M
Cash
$33.0M
Total Debt
$17.9M
As of Dec 31, 2025
How does BLFS compare to Life Sciences Tools & Services peers?
Peer group: Small-cap Life Sciences Tools & Services ($300M+) · 25 companies
BLFS valuation vs Life Sciences Tools & Services peers
P/E ratio
—
▼
0%
below
peers
(32.5)
vs Peers
vs Industry
Fair value
P/S ratio
15.7
▲
312%
above
peers
(3.8)
vs Peers
vs Industry
Overvalued
P/B ratio
3.4
▼
8%
below
peers
(3.7)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.5%)
vs Peers
vs Industry
Low yield
BLFS profitability vs Life Sciences Tools & Services peers
ROE
-0.9%
▲
72%
above
peers
(-3.3%)
vs Peers
vs Industry
Below avg
Net margin
-20.2%
▼
115%
below
peers
(-9.4%)
vs Peers
vs Industry
Weak
Gross margin
64.8%
▲
35%
above
peers
(48.0%)
vs Peers
vs Industry
Top tier
ROA
-0.8%
▲
69%
above
peers
(-2.6%)
vs Peers
vs Industry
Below avg
BLFS financial health vs Life Sciences Tools & Services peers
D/E ratio
2.1
▼
94%
below
peers
(36.5)
vs Peers
vs Industry
Low debt
Current ratio
4.7
▲
38%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.9
▲
36%
above
peers
(1.4)
vs Peers
vs Industry
More volatile
BLFS fundamentals radar
BLFS
Peer median
Industry
BLFS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
BLFS vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
FOSTER KAREN A
Chief Operating Officer · Mar 09
97423 shs
BERARD TODD C.J.
Officer · Mar 03
353 shs
MATHEW ABY J
Officer · Mar 03
529 shs
WICHTERMAN TROY
Chief Financial Officer · Mar 03
588 shs
WERNER SEAN
Chief Technology Officer · Mar 03
111 shs
FOSTER KAREN A
Officer · Mar 03
418 shs
AEBERSOLD SARAH
Officer · Mar 03
219 shs
WICHTERMAN TROY
Chief Financial Officer · Feb 24
96016 shs
WERNER SEAN
Chief Technology Officer · Feb 24
24116 shs
DE GREEF RODERICK
Chief Executive Officer · Feb 24
508045 shs
Last 90 days
Top Holders
Top 5: 49.83%Casdin Capital, LLC
12.33%
$110.7M
Blackrock Inc.
12.24%
$109.9M
T. Rowe Price Investment Ma…
10.73%
$96.3M
Invesco Ltd.
8.14%
$73.1M
Vanguard Group Inc
6.39%
$57.4M
As of Dec 31, 2025
Latest News
No related news yet